Biomarker & Intervention Discovery

Low Back Pain

This page lists 9 druggable gene targets, 21 approved or trial-tested drug candidates and 15 recent clinical trials for Low Back Pain, with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Candidates include existing drugs that could be repurposed. Sources are linked so you can check every claim.

US DALYs5.98MWHO GHE 2021 · all ages
Global DALYs90.46MWHO GHE 2021 · worldwide
US mortality1,573 deaths/yrWHO GHE 2021
Global mortality6,796 deaths/yrWHO GHE 2021 · worldwide
NIH funding$80MFY2025 · RCDC estimate
Funding levelSeverely Underfunded
Spontaneous remission~90% of acute LBP episodes resolve within 6 weeks regardless of treatment; chronic LBP (>3 months) shows only 30-40%…
Best-intervention remissionCognitive behavioral therapy (CBT) + graded exercise: 50-70% sustained improvement at 1 year in chronic LBP; Pain…
Gap sizeLarge for psychologically-informed approaches vs current opioid/surgical dominant model
Primary barrierpractice
Full remission profile →

Remission & chronicity

Spontaneous remission
~90% of acute LBP episodes resolve within 6 weeks regardless of treatment; chronic LBP (>3 months) shows only 30-40% recovery at 1 year and high recurrence; opioid prescribing correlates inversely with recovery
Best-intervention remission
Cognitive behavioral therapy (CBT) + graded exercise: 50-70% sustained improvement at 1 year in chronic LBP; Pain Reprocessing Therapy (PRT) — 66% pain-free or nearly pain-free at 1 year (JAMA Psychiatry 2021, vs 20% placebo); early active rehabilitation (vs bed rest) dramatically reduces chronification
Gap size
Large for psychologically-informed approaches vs current opioid/surgical dominant model
Primary barrier
practice
Opioid prescribing for chronic LBP is associated with worse long-term outcomes yet remains extremely common; spinal fusion surgery rates 40x higher in US than UK despite no superiority over conservative care in most indications; active rehabilitation demonstrably superior to passive treatment but requires patient effort and provider time

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

COMP 2GRIN1 183IL6 173NGF 9OPRM1 316PTGS2 299SCN9A 271TNF 277TRPV1 160
Therapeutic Agent Effect Direction Evidence Tier Potency Source
BC11-38 ↓ inhibits Mechanistic
TADALAFIL ↓ inhibits Mechanistic
Therapeutic Agent Effect Direction Evidence Tier Potency Source
COMPOUND 53 [PMID: 33038794] ↑ activates Mechanistic
PAREGORIC ? unclear Mechanistic
STING AGONIST 2 ↑ activates Mechanistic
LATREPIRDINE ? unclear Mechanistic
CNS-5161 ↓ inhibits Mechanistic
MEMANTINE HYDROCHLORIDE ~ modulates Mechanistic
LANICEMINE ↓ inhibits Mechanistic
ULEVOSTINAG ↑ activates Mechanistic
ELIPRODIL ? unclear Mechanistic
NBQX ? unclear Mechanistic
RAPASTINEL ? unclear Mechanistic
DEXANABINOL ? unclear Mechanistic
NEBOGLAMINE ~ modulates Mechanistic
HALOPERIDOL DECANOATE ? unclear Mechanistic
ORPHENADRINE ? unclear Mechanistic
GW468816 ↓ inhibits Mechanistic
ACAMPROSATE CALCIUM ↓ inhibits Mechanistic
AMANTADINE HYDROCHLORIDE ↓ inhibits Mechanistic
H-151 ↓ inhibits Mechanistic
D-SERINE ? unclear Mechanistic
AZD8108 ↓ inhibits Mechanistic
KETAMINE HYDROCHLORIDE ~ modulates Mechanistic
DELUCEMINE ↓ inhibits Mechanistic
EVT-101 ↓ inhibits Mechanistic
MSA-2 ↑ activates Mechanistic
ESKETAMINE HYDROCHLORIDE ? unclear Mechanistic
2'3'-CGAMP ↑ activates Mechanistic
COMPOUND 40 [PMID: 33470814] ↑ activates Mechanistic
PHILANTHOTOXIN 343 ? unclear Mechanistic
FELBAMATE ↓ inhibits Mechanistic
INDANTADOL ↓ inhibits Mechanistic
STING AGONIST 3 ↑ activates Mechanistic
ORPHENADRINE HYDROCHLORIDE ↓ inhibits Mechanistic
CYCLOSERINE ? unclear Mechanistic
RADIPRODIL ↓ inhibits Mechanistic
PERZINFOTEL ↓ inhibits Mechanistic
ESKETAMINE ~ modulates Mechanistic
ADU-S100 ↑ activates Mechanistic
RALFINAMIDE ↓ inhibits Mechanistic
SNX281 ↑ activates Mechanistic

Showing top 40 of 183 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CISPLATIN ? unclear Mechanistic
ZILTIVEKIMAB ~ modulates Mechanistic
CHINESE HERBS ? unclear Mechanistic
PF-04236921 ↓ inhibits Mechanistic
MRA 003 US ↓ inhibits Mechanistic
SIGNAL TRANSDUCTION INHIBITOR ? unclear Mechanistic
BINETRAKIN ? unclear Mechanistic
IBUDILAST ? unclear Mechanistic
INSULIN, REGULAR, HUMAN ? unclear Mechanistic
SILTUXIMAB ↓ inhibits Mechanistic
METRONIDAZOLE ? unclear Mechanistic
CLAZAKIZUMAB ↓ inhibits Mechanistic
GALLIUM NITRATE ? unclear Mechanistic
INTERFERON ALFA-2B ? unclear Mechanistic
DULOXETINE HYDROCHLORIDE ? unclear Mechanistic
MEDI-5117 ↓ inhibits Mechanistic
GEMFIBROZIL ? unclear Mechanistic
BIAFINE CREAM ? unclear Mechanistic
ETANERCEPT ? unclear Mechanistic
ELSILIMOMAB ↓ inhibits Mechanistic
SAQUINAVIR ? unclear Mechanistic
INFLIXIMAB ? unclear Mechanistic
LINEZOLID ? unclear Mechanistic
IFOSFAMIDE ? unclear Mechanistic
OLOKIZUMAB ↓ inhibits Mechanistic
HMG-COA REDUCTASE INHIBITOR ? unclear Mechanistic
MIDOSTAURIN ? unclear Mechanistic
SELENIUM ? unclear Mechanistic
SIRUKUMAB ↓ inhibits Mechanistic
PEGINTERFERON ALFA-2B ? unclear Mechanistic
ECHINACEA PREPARATION ? unclear Mechanistic
ENZYME INHIBITOR ? unclear Mechanistic
FENOFIBRATE MICRONIZED ? unclear Mechanistic
VITAMIN K ? unclear Mechanistic
PEGINTERFERON ALFA-2A ? unclear Mechanistic
RIBAVIRIN ? unclear Mechanistic
VITAMIN A PALMITATE ? unclear Mechanistic
ARSENIC TRIOXIDE ? unclear Mechanistic
DIHYDROSPHINGOSINE ? unclear Mechanistic
LEVOFLOXACIN ANHYDROUS ? unclear Mechanistic

Showing top 40 of 173 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
MEDI-578 ↓ inhibits Mechanistic
CERE-110 ? unclear Mechanistic
FASINUMAB ↓ inhibits Mechanistic
TANEZUMAB ↓ inhibits Mechanistic
FRUNEVETMAB ~ modulates Mechanistic
FULRANUMAB ↓ inhibits Mechanistic
BEDINVETMAB ~ modulates Mechanistic
PG-110 ↓ inhibits Mechanistic
CHEMBL1397270 ↓ inhibits Mechanistic 1000.0 nM (IC50)
Therapeutic Agent Effect Direction Evidence Tier Potency Source
DIFENOXIN HYDROCHLORIDE ↑ activates Mechanistic
SUMATRIPTAN ? unclear Mechanistic
DIACETYLMORPHINE ↑ activates Mechanistic
NALTALIMIDE ↑ activates Mechanistic
CLOCINNAMOX ? unclear Mechanistic
METHADONE HYDROCHLORIDE ↑ activates Mechanistic
NALTREXONE HYDROCHLORIDE ↓ inhibits Mechanistic
CP-866087 ↓ inhibits Mechanistic
PENTAZOCINE ? unclear Mechanistic
MONOAMINE OXIDASE INHIBITOR ? unclear Mechanistic
PAREGORIC ? unclear Mechanistic
NALOXONE HYDROCHLORIDE ↓ inhibits Mechanistic
BUPRENORPHINE ↑ activates Mechanistic
CEBRANOPADOL ↑ activates Mechanistic
OXYCODONE ↑ activates Mechanistic
CODEINE PHOSPHATE ↑ activates Mechanistic
AXELOPRAN ↓ inhibits Mechanistic
SAMIDORPHAN L-MALATE ↓ inhibits Mechanistic
ALFENTANIL HYDROCHLORIDE ↑ activates Mechanistic
TIANEPTINE ? unclear Mechanistic
METENKEFALIN ? unclear Mechanistic
SUFENTANIL ? unclear Mechanistic
OXYCODONE TEREPHTHALATE ↑ activates Mechanistic
LEVALLORPHAN TARTRATE ↓ inhibits Mechanistic
CHEMBL:CHEMBL409225 ? unclear Mechanistic
BUTORPHANOL ? unclear Mechanistic
LOPERAMIDE ↑ activates Mechanistic
CODEINE ANHYDROUS ↑ activates Mechanistic
ORP-101 ↑ activates Mechanistic
ANILERIDINE HYDROCHLORIDE ↑ activates Mechanistic
BEVENOPRAN ? unclear Mechanistic
IBUPROFEN, SODIUM SALT ? unclear Mechanistic
NALMEFENE ? unclear Mechanistic
NALOXONE HYDROCHLORIDE DIHYDRATE ↓ inhibits Mechanistic
METHYLSAMIDORPHAN ↓ inhibits Mechanistic
PHENCYCLIDINE HYDROCHLORIDE ? unclear Mechanistic
FENTANYL HYDROCHLORIDE ↑ activates Mechanistic
ELUXADOLINE ↑ activates Mechanistic
PROPOXYPHENE NAPSYLATE ↑ activates Mechanistic
PROPOXYPHENE ? unclear Mechanistic

Showing top 40 of 316 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CARPROFEN ↓ inhibits Mechanistic 102.0 nM (IC50)
INDOMETHACIN SODIUM ↓ inhibits Mechanistic
DARBUFELONE ? unclear Mechanistic
MEFENAMIC ACID ↓ inhibits Mechanistic
MECLOFENAMATE SODIUM ↓ inhibits Mechanistic
DICLOFENAC SODIUM ↓ inhibits Mechanistic
CAPECITABINE ? unclear Mechanistic
PIRPROFEN ↓ inhibits Mechanistic
ESFLURBIPROFEN ↓ inhibits Mechanistic
SULFASALAZINE ↓ inhibits Mechanistic
BROMFENAC ? unclear Mechanistic
IBUPROFEN, SODIUM SALT ↓ inhibits Mechanistic
ALOXIPRIN ↓ inhibits Mechanistic
TENOXICAM ? unclear Mechanistic
FLURBIPROFEN ↓ inhibits Mechanistic
SALICYLIC ACID ? unclear Mechanistic
ATENOLOL ? unclear Mechanistic
DEXKETOPROFEN ↓ inhibits Mechanistic
ETORICOXIB ↓ inhibits Mechanistic
LUMIRACOXIB ↓ inhibits Mechanistic
SUPROFEN ↓ inhibits Mechanistic
NS-398 ? unclear Mechanistic
NABUMETONE ↓ inhibits Mechanistic
URSOLIC ACID ? unclear Mechanistic
IBUPROFEN LYSINE ↓ inhibits Mechanistic
ACECLOFENAC ↓ inhibits Mechanistic
IBUFENAC ↓ inhibits Mechanistic
BALSALAZIDE ? unclear Mechanistic
DIFLUNISAL ↓ inhibits Mechanistic
BALSALAZIDE DISODIUM ↓ inhibits Mechanistic
VACCINE ? unclear Mechanistic
KETOROLAC TROMETHAMINE ↓ inhibits Mechanistic
BENZYDAMINE HYDROCHLORIDE ↓ inhibits Mechanistic
TIAPROFENIC ACID ? unclear Mechanistic
RALOXIFENE HYDROCHLORIDE ? unclear Mechanistic
NAPROXCINOD ↓ inhibits Mechanistic
IGURATIMOD ↓ inhibits Mechanistic
ETODOLAC ↓ inhibits Mechanistic
DICLOFENAC ETALHYALURONATE SODIUM ↓ inhibits Mechanistic
ROFECOXIB ↓ inhibits Mechanistic 530.0 nM (IC50)

Showing top 40 of 299 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
MERETHOXYLLINE PROCAINE ↓ inhibits Mechanistic
ETIDOCAINE HYDROCHLORIDE ↓ inhibits Mechanistic
FOSPHENYTOIN ↓ inhibits Mechanistic
VERATRIDINE ↑ activates Mechanistic
ORPHENADRINE CITRATE ↓ inhibits Mechanistic
PHENACEMIDE ↓ inhibits Mechanistic
LACOSAMIDE ↓ inhibits Mechanistic
VIXOTRIGINE ↓ inhibits Mechanistic
DSP-2230 ↓ inhibits Mechanistic
SAXITOXIN ↓ inhibits Mechanistic
ESLICARBAZEPINE ACETATE ↓ inhibits Mechanistic
SAFINAMIDE ? unclear Mechanistic
LIDOCAINE ↓ inhibits Mechanistic
RILUZOLE ↓ inhibits Mechanistic
ROPIVACAINE HYDROCHLORIDE ↓ inhibits Mechanistic
FUNAPIDE ↓ inhibits Mechanistic
DYCLONINE HYDROCHLORIDE ↓ inhibits Mechanistic
EVENAMIDE ↓ inhibits Mechanistic
PROPOFOL ? unclear Mechanistic
AM-6120 ↓ inhibits Mechanistic
RG7893 ↓ inhibits Mechanistic
RG6029 ↓ inhibits Mechanistic
QUINIDINE SULFATE ↓ inhibits Mechanistic
ZONISAMIDE ↓ inhibits Mechanistic
NERISPIRDINE ↓ inhibits Mechanistic
RALFINAMIDE ↓ inhibits Mechanistic
DS-1971A ↓ inhibits Mechanistic
HEXYLCAINE HYDROCHLORIDE ↓ inhibits Mechanistic
MEPIVACAINE HYDROCHLORIDE ↓ inhibits Mechanistic
PROCAINAMIDE HYDROCHLORIDE ↓ inhibits Mechanistic
PROPAFENONE HYDROCHLORIDE ↓ inhibits Mechanistic
LIDOCAINE HYDROCHLORIDE ↓ inhibits Mechanistic
QUINIDINE GLUCONATE ↓ inhibits Mechanistic
PRILOCAINE ↓ inhibits Mechanistic
ETHOTOIN ↓ inhibits Mechanistic
PF-05089771 ↓ inhibits Mechanistic
DICHLOROBENZYL ALCOHOL ↓ inhibits Mechanistic
RANOLAZINE ? unclear Mechanistic
PRILOCAINE HYDROCHLORIDE ↓ inhibits Mechanistic
ORPHENADRINE HYDROCHLORIDE ↓ inhibits Mechanistic

Showing top 40 of 271 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
NERELIMOMAB ↓ inhibits Mechanistic
CROMOLYN SODIUM ? unclear Mechanistic
PLACULUMAB ↓ inhibits Mechanistic
METHYLENE BLUE ? unclear Mechanistic
ALTEPLASE ? unclear Mechanistic
CARBOPLATIN ? unclear Mechanistic
GENTAMICIN ? unclear Mechanistic
GOLIMUMAB ↓ inhibits Mechanistic
BUPIVACAINE ? unclear Mechanistic
PENTOXIFYLLINE ? unclear Mechanistic 85000.0 nM (IC50)
BENZO[E]PYRENE ? unclear Mechanistic
THALIDOMIDE ? unclear Mechanistic
PYRAZINAMIDE ? unclear Mechanistic
GLIMEPIRIDE ? unclear Mechanistic
OMEPRAZOLE ? unclear Mechanistic
LENERCEPT ↓ inhibits Mechanistic
ADALIMUMAB ↓ inhibits Mechanistic
PRAZOSIN HYDROCHLORIDE ? unclear Mechanistic
REMTOLUMAB ? unclear Mechanistic
MIDOSTAURIN ? unclear Mechanistic
LENABASUM ? unclear Mechanistic
MAGNESIUM SULFATE ANHYDROUS ? unclear Mechanistic
PICIBANIL ? unclear Mechanistic
FLUOCINOLONE ACETONIDE ? unclear Mechanistic
MILTEFOSINE ? unclear Mechanistic
HOMIDIUM BROMIDE ? unclear Mechanistic
OZORALIZUMAB ↓ inhibits Mechanistic
PEGSUNERCEPT ↓ inhibits Mechanistic
CERTOLIZUMAB PEGOL ↓ inhibits Mechanistic
THERAPEUTIC HORMONE ? unclear Mechanistic
NAFAMOSTAT ? unclear Mechanistic
FOLIC ACID ? unclear Mechanistic
ABBV-257 ? unclear Mechanistic
RISPERIDONE ? unclear Mechanistic
COVA322 ? unclear Mechanistic
HYDROXYCHLOROQUINE ? unclear Mechanistic
CERTOLIZUMAB ? unclear Mechanistic
AN0128 ? unclear Mechanistic
5,7-DIHYDROXY-4-METHYLCOUMARIN ? unclear Mechanistic
SORAFENIB ? unclear Mechanistic

Showing top 40 of 277 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
STREPTOZOCIN ? unclear Mechanistic
BENZYL ISOTHIOCYANATE ? unclear Mechanistic
ACETAMINOPHEN ↑ activates Mechanistic
POLYGODIAL ? unclear Mechanistic
PROPOFOL ? unclear Mechanistic
SAF312 ↓ inhibits Mechanistic
GRC-15300 ? unclear Mechanistic
AZD1386 ↓ inhibits Mechanistic
TIVANISIRAN ↓ inhibits Mechanistic
MAVATREP ↓ inhibits Mechanistic
MR-1817 ↓ inhibits Mechanistic
FERRUGINENE B ? unclear Mechanistic
CAPSAICIN ↑ activates Mechanistic 19.95 nM (EC50)
RECOMBINANT TUMOR NECROSIS FACTOR FAMILY PROTEIN ? unclear Mechanistic
PHENETHYLISOTHIOCYANATE ? unclear Mechanistic
VOACANGINE ? unclear Mechanistic
RESINIFERATOXIN ↑ activates Mechanistic 23.1 nM (Ki)
DWP05195 ↓ inhibits Mechanistic
XEN-D0501 ↓ inhibits Mechanistic
PAC-14028 ↓ inhibits Mechanistic
SB-705498 ↓ inhibits Mechanistic
MASOPROCOL ? unclear Mechanistic
ALLYL ISOTHIOCYANATE ? unclear Mechanistic
NGD-8243 ↓ inhibits Mechanistic
GRC-6211 ↓ inhibits Mechanistic
RESERPINE ? unclear Mechanistic
NABIXIMOLS ? unclear Mechanistic
A425619 ? unclear Mechanistic
PHE377 ↓ inhibits Mechanistic
ANTISENSE OLIGONUCLEOTIDES ? unclear Mechanistic
WORTMANNIN ? unclear Mechanistic
JTS-653 ↓ inhibits Mechanistic
LEVODOPA ? unclear Mechanistic
AMG517 ↓ inhibits Mechanistic
CAPSAZEPINE ? unclear Mechanistic 120.0 nM (Ki)
ZUCAPSAICIN ↑ activates Mechanistic
INDOMETHACIN ? unclear Mechanistic
CHEMBL:CHEMBL191534 ? unclear Mechanistic
ABT-102 ↓ inhibits Mechanistic
ISOPROPYL ISOTHIOCYANATE ? unclear Mechanistic

Showing top 40 of 160 agents ranked by evidence tier.


Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Low Back Pain: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

NCT07837596 Phase: N/A Started: 2022-03-07

This prospective randomized controlled trial evaluated the effectiveness and safety of adjunctive wet cupping therapy combined with standard pharmacological treatment in adults presenting to the emergency department with acute non-specific low back pain. A total of 80 adult patients were randomly as...

NCT06859957 Phase: 3 Started: 2025-04-11

Low back pain is one of the conditions causing more disability worldwide. The use of pain medications is substantial in patients with chronic LBP. But the efficacy of commonly used analgesics is modest. More than half of patients with chronic LBP also has sleep problems. In recent years, some prelim...

NCT04772781 Phase: 2 Started: 2022-06-03

The purpose of this study is to evaluate the efficacy of S (+) - ibuprofen compared to an active treatment for pain control in individuals with at least moderate acute mechanical low back pain.

NCT06355414 Phase: 1 Started: 2024-04-22

This study seeks to provide insight on psilocybin's effects on mechanisms of chronic pain among patients with co-morbid chronic low back pain and depression (CLBP+D). Participants will receive either a single high-dose of psilocybin (25mg absolute dose) or methylphenidate (40mg absolute dose). Parti...

NCT04747314 Phase: 2 Started: 2021-03-31

This study will examine how the use of antidepressant, physical therapy, and combination of both affects pain, function, and depression outcomes in chronic low back pain patients.

NCT06053242 Phase: 1/2 Started: 2024-05-21

The brief purpose of this research study is to learn about the safety, tolerability, and efficacy of paraspinal intramuscular injection of CELZ-201-DDT in patients with chronic lower back pain.

NCT07772141 Phase: N/A Started: 2026-01-01

Low back pain (LBP) is a public and occupational health problem that is a major professional, economic and social burden. Up to 84% of the general population will experience an episode of LBP during its life time, and recurrence rates are high. Acute LBP is the second reason for consultations in gen...

NCT07709416 Phase: N/A Started: 2026-07-15

Chronic non-specific low back pain is the leading cause of productivity loss and disability worldwide, constituting a major public health challenge. This study aims to systematically evaluate and compare the role of the antidepressant drug toludesvenlafaxine in chronic non-specific low back pain, wh...

NCT06001853 Phase: 2 Started: 2023-11-03

The purpose of this research study is to evaluate the safety and effect of bone marrow-derived stem cells for the treatment of low back pain.

NCT07675304 Phase: Early 1 Started: 2026-05-06

The aim of this study is to evaluate the effectiveness of collagen mesotherapy in the treatment of chronic low back pain (CLBP) in the lumbosacral spine. Mesotherapy is expected to reduce pain in the lumbosacral region, decrease soft tissue tension (including muscles, fascia, and ligaments), improve...

NCT06471998 Phase: 2 Started: 2025-02-28

The purpose of this study is to evaluate the benefit of Localized Tissue Hydration associated with standard management of chronic common low back pain, in terms of improvement in the numerical verbal scale score at 6 months.

NCT04611529 Phase: 4 Started: 2021-03-02

This is a randomized, double-blind placebo-controlled study comparing two different treatments for acute low back pain: oral ibuprofen and topical diclofenac. Participants will be randomized to one of three study arms: 1) Oral ibuprofen + topical diclofenac; 2) Oral ibuprofen + topical placebo; 3) O...

NCT06454669 Phase: 2 Started: 2024-06-15

This exploratory, proof-of-concept study is a double-blind (participants and investigators will be blinded), placebo-controlled, randomized, two-arm clinical trial of Marinol \[dronabinol, synthetic Δ9-tetrahydrocannabinol (THC)\] for chronic low back pain (cLBP) with a 2:1 allocation ratio. Up to 7...

NCT07241559 Phase: N/A Started: 2025-11-01

The aim of this study is to investigate the effects of thoracolumbar fascia mobilization and ultrasound-guided thoracolumbar interfascial 5% dextrose injection on pain, range of motion, disability, quality of life, proprioception, and fascial thickness and echogenicity in patients with nonspecific c...

NCT05351541 Phase: 1/2 Started: 2023-12-01

This study evaluates whether psilocybin therapy helps patients cope with chronic low back pain more effectively. Patients may be recruited at Stanford and University of California San Francisco (UCSF), study procedures will occur at UCSF. Each participant will receive a dose of psilocybin with possi...


Agents Found By Disease-Level Search

Searched directly from “Low Back Pain” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 9-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

21 agents shown (approved or with trial evidence) — 20 not found by the gene-target search above.

Carisoprodol SRNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT00671502 NCT00671502

HeatTens (HV-F311-E)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03643731

BM-MSC injectionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06001853

DSMO InjectionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06001853

CLEVERNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06506604

UltrasonographyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05206136

LumbaCure®NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06662032

ReActiv8NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04803214

Tapentadol (CG5503) Extended Release (ER)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00487435

Tapentadol Prolonged ReleaseNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01838616

Oxycodone/Naloxone Prolonged ReleaseNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01838616

SFEX+HNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03031158

SFEXNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03031158

DZeroNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07274293

Caudal epidural injectionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00370799

Caudal Epidural Injection with generic CelestoneNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00370799

Caudal Epidural Injection with CelestoneNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00370799

Caudal Epidural Injection with DepoMedrolNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00370799

Dextrose 15% and lidocaine 1% infiltrationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07296653

Lidocaine 1% infiltrationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07296653

BUPRENORPHINE

Approved · 0 trials · source: Open Targets

Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.